This is the classic website, which will be retired eventually. Please visit the modernized ClinicalTrials.gov instead.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    ES009-1001
Previous Study | Return to List | Next Study

A Study of ES009 in Subjects With Locally Advanced or Metastatic Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT06007482
Recruitment Status : Recruiting
First Posted : August 23, 2023
Last Update Posted : November 15, 2023
Sponsor:
Information provided by (Responsible Party):
Elpiscience Biopharma, Ltd. ( Elpiscience Biopharma Australia Pty. Ltd. )

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The goal of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary clinical activity of ES009 administered intravenously to subjects with advanced solid tumors.

Condition or disease Intervention/treatment Phase
Advanced Solid Tumor Drug: ES009 Phase 1

Detailed Description:

ES009 is a recombinant humanized IgG4 monoclonal antibody that specifically targets and blocks LILRB2. By reprograming suppressive myeloid cells into pro-inflammatory phenotypes, ES009 reshapes the immunosuppressive tumor microenvironment into an immune-favorable one to combat cancer development and progression.

This is a first-in-human, open-label, multicenter, non-randomized study designed to determine the maximum tolerated dose (MTD)/maximum administered dose (MAD), optimal biological dose (OBD), and recommended phase 2 dose (RP2D) of ES009 by evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary clinical activity of ES009 administered intravenously to subjects with advanced solid tumors.

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Allocation: N/A
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-Label, Multicenter, First-in-Human, Phase 1 Study of ES009 in Subjects With Locally Advanced or Metastatic Solid Tumors
Actual Study Start Date : September 7, 2023
Estimated Primary Completion Date : August 15, 2024
Estimated Study Completion Date : August 15, 2025
Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Dose Escalation Cohort
ES009 monotherapy dose level will be escalated in participants with advanced solid tumors.
 Drug: ES009
ES009 is administered via intravenous infusion, once every 21 days.


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. The frequency and severity of adverse events of ES009 [ Time Frame: 1-3 years ]
    Adverse events will be assessed and assigned by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0.

  2. Maximum tolerated dose (MTD) of ES009 [ Time Frame: 1-3 years ]
    The MTD of ES009 will be determined.

  3. Optimal biological dose (OBD) of ES009 [ Time Frame: 1-3 years ]
    The OBD of ES009 will be determined.

  4. Recommended phase 2 dose (RP2D) of ES009 [ Time Frame: 1-3 years ]
    The RP2D of ES009 will be determined.

  5. Maximum administered dose (MAD) of ES009 [ Time Frame: 1-3 years ]
    The MAD of ES009 will be determined.


Secondary Outcome Measures :
  1. Maximum observed serum concentration (Cmax) of ES009 [ Time Frame: 1-3 years ]
    Maximum observed serum concentration (Cmax) of ES009 will be measured.

  2. Trough observed serum concentration (Ctrough) of ES009 [ Time Frame: 1-3 years ]
    Trough observed serum concentration (Ctrough)of ES009 will be measured.

  3. Area under the serum concentration time curve (AUC) of ES009 [ Time Frame: 1-3 years ]
    Area under the serum concentration time curve (AUC) of ES009 will be measured.

  4. Time to Cmax (Tmax) of ES009 [ Time Frame: 1-3 years ]
    Time to Cmax (Tmax) of ES009 will be measured.

  5. The terminal elimination half life of ES009 [ Time Frame: 1-3 years ]
    The terminal elimination half-life (t 1/2) of ES009 will be measured.

  6. Immunogenicity of ES009 [ Time Frame: 1-3 years ]
    Frequency of anti-drug antibodies (ADA) against ES009 will be determined.

  7. Preliminary antitumor activity of ES009 [ Time Frame: 1-3 years ]
    Tumor response will be measured by the revised Response Evaluation Criteria in Solid Tumors version 1.1 (RECISTv1.1) by Investigator assessment.


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Capable of giving signed informed consent.
  • Histological or cytological documentation of unresectable locally advanced or metastatic solid tumors, if 1) disease has progressed despite standard therapy, and no further standard therapy exists; or 2) standard therapy has proven to be ineffective or intolerable or is considered inappropriate.
  • At least one measurable lesion per RECIST v1.1.
  • Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-1.
  • Life expectancy of at least 12 weeks.
  • Adequate hematologic, hepatic, renal and coagulation function per protocol.
  • Male and female subjects of childbearing potential must be willing to completely abstain or agree to use a highly effective method of contraception per protocol.

Exclusion Criteria:

  • Any prior therapy targeting LILRB2.
  • Receipt of any investigational therapies within 28 days or 5 half-lives prior to the first dose of study drug.
  • Prior treatment with the following therapies:• Anticancer therapy within 28 days or 5 half-lives of the drug prior to the first dose of study drug, whichever is shorter. Exception: hormonal replacement therapy.• A wash out of at least 2 weeks before the start of study drug for radiation to the extremities and 4 weeks for radiation to the chest, brain, or visceral organs is required.
  • Prior allogeneic or autologous bone marrow transplantation or solid organ transplantation.
  • Toxicity from previous anticancer treatment per protocol.
  • Treatment with systemic immunosuppressive medications within 4 weeks prior to the first dose of study drug with certain exceptions.
  • Subjects who received transfusion of blood products (including platelets or red blood cells), G-CSF, GM-CSF, recombinant erythropoietin, or recombinant thrombopoietin within 14 days prior to the first dose of study treatment.
  • Major surgery within 4 weeks prior to the first dose of study treatment.
  • Live vaccine therapies within 4 weeks prior to the first dose of study treatment.
  • Recent history of allergen desensitization therapy within 4 weeks prior to the first dose of study treatment.
  • Known allergies to CHO-produced antibodies.
  • Invasive malignancy or history of invasive malignancy other than disease under study within the last two years with certain exceptions.
  • CNS metastases with certain exceptions.
  • Active autoimmune disease or documented history of autoimmune disease that required systemic steroids or other immunosuppressive medications.
  • Active interstitial lung disease (ILD) or pneumonitis requiring treatment with steroids or other immunosuppressive medications.
  • Active infection requiring systemic therapy, known human immunodeficiency virus (HIV) infection, or positive test for hepatitis B active infection (HBsAg) or hepatitis C active infection (hepatitis C antibody).
  • Current active liver or biliary disease (with the exception of Gilbert's syndrome or asymptomatic gallstones, liver metastases, or otherwise stable chronic liver disease per investigator assessment).
  • History or evidence of cardiac abnormalities.
  • Pregnant or nursing females.
  • Any known, documented, or suspected history of illicit substance abuse that would preclude subject from participation, unless clinically justified.
  • Any other disease or clinically significant abnormality in laboratory parameters, including serious medical or psychiatric illness/condition, which in the judgment of the Investigator might compromise the safety of the subject or integrity of the study, interfere with the subject participation in the trial or compromise the trial objectives.
  • Involvement in the planning and/or conduct of the study (applies to both Sponsor/CRO staff and staff at the study site)
  • Judgment by the Investigator that the subject is unlikely to comply with study procedures, restrictions and requirements.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT06007482


Contacts
Layout table for location contacts
Contact: Sydney Gong, PM 86-021-50651310 clinical-operation@elpiscience.com

Locations
Layout table for location information
Australia
Peninsula and South Eastern Oncology and Haematology Group Recruiting
Frankston, Australia
Contact: Vinod Ganju         
St George Private Hospital Not yet recruiting
Kogarah, Australia
Contact: Paul De Souza         
Scientia Clinical Research Recruiting
Randwick, Australia
Contact: Charlotte Lemech         
Sunshine Coast University Private Hospital Not yet recruiting
Sunshine Coast, Australia
Contact: Michelle Morris         
Sponsors and Collaborators
Elpiscience Biopharma Australia Pty. Ltd.
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Elpiscience Biopharma Australia Pty. Ltd.
ClinicalTrials.gov Identifier: NCT06007482    
Other Study ID Numbers: ES009-1001
First Posted: August 23, 2023    Key Record Dates
Last Update Posted: November 15, 2023
Last Verified: September 2023

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Elpiscience Biopharma, Ltd. ( Elpiscience Biopharma Australia Pty. Ltd. ):
Leukocyte immunoglobulin-like receptor B2 (LILRB2)
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms